Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02548351




Registration number
NCT02548351
Ethics application status
Date submitted
1/09/2015
Date registered
14/09/2015
Date last updated
1/10/2024

Titles & IDs
Public title
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Scientific title
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Secondary ID [1] 0 0
747-303
Universal Trial Number (UTN)
Trial acronym
REGENERATE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non Alcoholic Steatohepatitis (NASH) 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Diet and Nutrition 0 0 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: 10 mg Obeticholic Acid - 10 mg Obeticholic Acid daily for the remainder of the study

Experimental: 25 mg Obeticholic Acid - 25 mg Obeticholic Acid daily for the remainder of the study

Placebo comparator: Placebo - One tablet daily for the remainder of the study
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to the First Adjudicated Event for Clinical Outcome Composite Endpoint: Percentage of Participants With an Event
Timepoint [1] 0 0
Up to 7 years
Secondary outcome [1] 0 0
Percentage of Responders With Improvement of Fibrosis by at Least One Stage With no Worsening of NASH Using Consensus Read Method of Scheduled Liver Biopsies
Timepoint [1] 0 0
Up to 7 years
Secondary outcome [2] 0 0
Percentage of Participants Who Showed Improvement in Fibrosis by at Least 1 Stage and/or Resolution of NASH Without Worsening of Either Using Consensus Read Method
Timepoint [2] 0 0
Up to 7 years
Secondary outcome [3] 0 0
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timepoint [3] 0 0
Up to 7 years

Eligibility
Key inclusion criteria
1. Histologic evidence of NASH upon central read of a liver biopsy obtained no more than 6 months before Day 1 defined by presence of all 3 key histological features of NASH according to NASH CRN criteria.
2. Histologic evidence of fibrosis stage 2 or stage 3 as defined by the NASH CRN scoring of fibrosis, or

Histologic evidence of fibrosis stage 1a or stage 1b if accompanied by =1 of the following risk factors:
* Obesity (BMI =30 kg/m2)
* Type 2 diabetes diagnosed per 2013 American Diabetes Association criteria
* ALT >1.5× upper limit of normal (ULN).
3. For subjects with a historical biopsy, is either not taking or is on stable doses of TZDs/glitazones or vitamin E for 6 months before Day 1.
4. Stable body weight.
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Model for End-stage Liver Disease (MELD) score >12
2. ALT =10× ULN
3. HbA1c >9.5%
4. Total bilirubin >1.5 mg/dL
5. Evidence of other known forms of known chronic liver disease such as alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC)
6. History of liver transplant, or current placement on a liver transplant list
7. Current or history of significant alcohol consumption
8. Prior or planned ileal resection, or prior or planned bariatric surgery
9. Histological presence of cirrhosis
10. History of biliary diversion
11. Known positivity for human immunodeficiency virus infection.
12. Acute cholecystitis or acute biliary obstruction.
13. BMI >45 kg/m2

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/09/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
15/09/2023
Sample size
Target
Accrual to date
Final
2477
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Adelaide Hospital Gastroenterology and Hepatology Dept. - Adelaide
Recruitment hospital [2] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [3] 0 0
AW Morrow Gastroenterology and Liver Centre Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [4] 0 0
Monash Health - Monash Medical Centre - Clayton
Recruitment hospital [5] 0 0
Gallipoli Medical Research Foundation - Greenslopes
Recruitment hospital [6] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [7] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [8] 0 0
Nepean Hospital - Kingswood
Recruitment hospital [9] 0 0
The Alfred Hospital, Department of Gastroenterology - Melbourne
Recruitment hospital [10] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [11] 0 0
The Royal Melbourne Hospital - Parkville
Recruitment hospital [12] 0 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
2050 - Camperdown
Recruitment postcode(s) [4] 0 0
3168 - Clayton
Recruitment postcode(s) [5] 0 0
4120 - Greenslopes
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
4029 - Herston
Recruitment postcode(s) [8] 0 0
2747 - Kingswood
Recruitment postcode(s) [9] 0 0
3004 - Melbourne
Recruitment postcode(s) [10] 0 0
6150 - Murdoch
Recruitment postcode(s) [11] 0 0
3053 - Parkville
Recruitment postcode(s) [12] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Hawaii
Country [10] 0 0
United States of America
State/province [10] 0 0
Idaho
Country [11] 0 0
United States of America
State/province [11] 0 0
Illinois
Country [12] 0 0
United States of America
State/province [12] 0 0
Indiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Kansas
Country [14] 0 0
United States of America
State/province [14] 0 0
Kentucky
Country [15] 0 0
United States of America
State/province [15] 0 0
Louisiana
Country [16] 0 0
United States of America
State/province [16] 0 0
Maryland
Country [17] 0 0
United States of America
State/province [17] 0 0
Massachusetts
Country [18] 0 0
United States of America
State/province [18] 0 0
Michigan
Country [19] 0 0
United States of America
State/province [19] 0 0
Minnesota
Country [20] 0 0
United States of America
State/province [20] 0 0
Mississippi
Country [21] 0 0
United States of America
State/province [21] 0 0
Missouri
Country [22] 0 0
United States of America
State/province [22] 0 0
Nebraska
Country [23] 0 0
United States of America
State/province [23] 0 0
New Jersey
Country [24] 0 0
United States of America
State/province [24] 0 0
New Mexico
Country [25] 0 0
United States of America
State/province [25] 0 0
New York
Country [26] 0 0
United States of America
State/province [26] 0 0
North Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Ohio
Country [28] 0 0
United States of America
State/province [28] 0 0
Oklahoma
Country [29] 0 0
United States of America
State/province [29] 0 0
Pennsylvania
Country [30] 0 0
United States of America
State/province [30] 0 0
Rhode Island
Country [31] 0 0
United States of America
State/province [31] 0 0
South Carolina
Country [32] 0 0
United States of America
State/province [32] 0 0
South Dakota
Country [33] 0 0
United States of America
State/province [33] 0 0
Tennessee
Country [34] 0 0
United States of America
State/province [34] 0 0
Texas
Country [35] 0 0
United States of America
State/province [35] 0 0
Utah
Country [36] 0 0
United States of America
State/province [36] 0 0
Vermont
Country [37] 0 0
United States of America
State/province [37] 0 0
Virginia
Country [38] 0 0
United States of America
State/province [38] 0 0
Washington
Country [39] 0 0
United States of America
State/province [39] 0 0
Wisconsin
Country [40] 0 0
Austria
State/province [40] 0 0
Innsbruck
Country [41] 0 0
Austria
State/province [41] 0 0
Klagenfurt
Country [42] 0 0
Austria
State/province [42] 0 0
Linz
Country [43] 0 0
Austria
State/province [43] 0 0
Salzburg
Country [44] 0 0
Austria
State/province [44] 0 0
Wien
Country [45] 0 0
Belgium
State/province [45] 0 0
Antwerpen
Country [46] 0 0
Belgium
State/province [46] 0 0
Brabant
Country [47] 0 0
Belgium
State/province [47] 0 0
Vlaams-Brabant
Country [48] 0 0
Belgium
State/province [48] 0 0
Brugge
Country [49] 0 0
Belgium
State/province [49] 0 0
Brussels
Country [50] 0 0
Belgium
State/province [50] 0 0
Genk
Country [51] 0 0
Belgium
State/province [51] 0 0
Ghent
Country [52] 0 0
Belgium
State/province [52] 0 0
Sint-Niklaas
Country [53] 0 0
Canada
State/province [53] 0 0
Ontario
Country [54] 0 0
Canada
State/province [54] 0 0
Calgary
Country [55] 0 0
Canada
State/province [55] 0 0
Edmonton
Country [56] 0 0
Canada
State/province [56] 0 0
Montreal
Country [57] 0 0
Canada
State/province [57] 0 0
Toronto
Country [58] 0 0
Canada
State/province [58] 0 0
Vancouver
Country [59] 0 0
Canada
State/province [59] 0 0
Victoria
Country [60] 0 0
Canada
State/province [60] 0 0
Winnipeg
Country [61] 0 0
Denmark
State/province [61] 0 0
Aalborg
Country [62] 0 0
Denmark
State/province [62] 0 0
Aarhus
Country [63] 0 0
Denmark
State/province [63] 0 0
Hvidovre
Country [64] 0 0
Denmark
State/province [64] 0 0
Odense
Country [65] 0 0
Finland
State/province [65] 0 0
Helsinki
Country [66] 0 0
Finland
State/province [66] 0 0
Turku
Country [67] 0 0
France
State/province [67] 0 0
Amiens
Country [68] 0 0
France
State/province [68] 0 0
Angers
Country [69] 0 0
France
State/province [69] 0 0
Bourgoin-Jallieu
Country [70] 0 0
France
State/province [70] 0 0
Clichy
Country [71] 0 0
France
State/province [71] 0 0
Creteil
Country [72] 0 0
France
State/province [72] 0 0
Grenoble
Country [73] 0 0
France
State/province [73] 0 0
Lille
Country [74] 0 0
France
State/province [74] 0 0
Lyon
Country [75] 0 0
France
State/province [75] 0 0
Marseille
Country [76] 0 0
France
State/province [76] 0 0
Nice
Country [77] 0 0
France
State/province [77] 0 0
Orléans
Country [78] 0 0
France
State/province [78] 0 0
Paris
Country [79] 0 0
France
State/province [79] 0 0
Pessac
Country [80] 0 0
France
State/province [80] 0 0
Rouen
Country [81] 0 0
France
State/province [81] 0 0
Toulouse
Country [82] 0 0
France
State/province [82] 0 0
Vandoeuvre-Lès-Nancy
Country [83] 0 0
France
State/province [83] 0 0
Villejuif
Country [84] 0 0
Germany
State/province [84] 0 0
Baden-Wurttemberg
Country [85] 0 0
Germany
State/province [85] 0 0
Bavaria
Country [86] 0 0
Germany
State/province [86] 0 0
Rhineland-Palatinate
Country [87] 0 0
Germany
State/province [87] 0 0
Saxony
Country [88] 0 0
Germany
State/province [88] 0 0
Aachen
Country [89] 0 0
Germany
State/province [89] 0 0
Berlin
Country [90] 0 0
Germany
State/province [90] 0 0
Bochum
Country [91] 0 0
Germany
State/province [91] 0 0
Cologne
Country [92] 0 0
Germany
State/province [92] 0 0
Essen
Country [93] 0 0
Germany
State/province [93] 0 0
Hamburg
Country [94] 0 0
Germany
State/province [94] 0 0
Hannover
Country [95] 0 0
Germany
State/province [95] 0 0
Herne
Country [96] 0 0
Germany
State/province [96] 0 0
Kiel
Country [97] 0 0
Germany
State/province [97] 0 0
Leipzig
Country [98] 0 0
Germany
State/province [98] 0 0
Munich
Country [99] 0 0
Germany
State/province [99] 0 0
Würzburg
Country [100] 0 0
Hungary
State/province [100] 0 0
Budapest
Country [101] 0 0
Hungary
State/province [101] 0 0
Debrecen
Country [102] 0 0
Israel
State/province [102] 0 0
Be'er Sheva
Country [103] 0 0
Israel
State/province [103] 0 0
Haifa
Country [104] 0 0
Israel
State/province [104] 0 0
Jerusalem
Country [105] 0 0
Israel
State/province [105] 0 0
Nahariya
Country [106] 0 0
Israel
State/province [106] 0 0
Nazareth
Country [107] 0 0
Israel
State/province [107] 0 0
Petach Tikva
Country [108] 0 0
Israel
State/province [108] 0 0
Ramat Gan
Country [109] 0 0
Israel
State/province [109] 0 0
Tel Aviv
Country [110] 0 0
Italy
State/province [110] 0 0
Bologna
Country [111] 0 0
Italy
State/province [111] 0 0
Milano
Country [112] 0 0
Italy
State/province [112] 0 0
Milan
Country [113] 0 0
Italy
State/province [113] 0 0
Modena
Country [114] 0 0
Italy
State/province [114] 0 0
Napoli
Country [115] 0 0
Italy
State/province [115] 0 0
Palermo
Country [116] 0 0
Italy
State/province [116] 0 0
Rome
Country [117] 0 0
Italy
State/province [117] 0 0
Rozzano
Country [118] 0 0
Italy
State/province [118] 0 0
Torino
Country [119] 0 0
New Zealand
State/province [119] 0 0
Auckland
Country [120] 0 0
Poland
State/province [120] 0 0
Gdansk
Country [121] 0 0
Poland
State/province [121] 0 0
Katowice
Country [122] 0 0
Poland
State/province [122] 0 0
Lodz
Country [123] 0 0
Poland
State/province [123] 0 0
Lublin
Country [124] 0 0
Poland
State/province [124] 0 0
Wroclaw
Country [125] 0 0
Portugal
State/province [125] 0 0
Aveiro
Country [126] 0 0
Portugal
State/province [126] 0 0
Beja
Country [127] 0 0
Portugal
State/province [127] 0 0
Guimarães
Country [128] 0 0
Portugal
State/province [128] 0 0
Lisboa
Country [129] 0 0
Portugal
State/province [129] 0 0
Lisbon
Country [130] 0 0
Puerto Rico
State/province [130] 0 0
San Juan
Country [131] 0 0
Serbia
State/province [131] 0 0
Belgrade
Country [132] 0 0
Serbia
State/province [132] 0 0
Nis
Country [133] 0 0
Spain
State/province [133] 0 0
Baleares
Country [134] 0 0
Spain
State/province [134] 0 0
Madrid
Country [135] 0 0
Spain
State/province [135] 0 0
Alcorcón
Country [136] 0 0
Spain
State/province [136] 0 0
Alicante
Country [137] 0 0
Spain
State/province [137] 0 0
Barcelona
Country [138] 0 0
Spain
State/province [138] 0 0
Leon
Country [139] 0 0
Spain
State/province [139] 0 0
Malaga
Country [140] 0 0
Spain
State/province [140] 0 0
San Sebastian
Country [141] 0 0
Spain
State/province [141] 0 0
Santander
Country [142] 0 0
Spain
State/province [142] 0 0
Santiago de Compostela
Country [143] 0 0
Spain
State/province [143] 0 0
Sevilla
Country [144] 0 0
Spain
State/province [144] 0 0
Valencia
Country [145] 0 0
Spain
State/province [145] 0 0
Zaragoza
Country [146] 0 0
Sweden
State/province [146] 0 0
Gothenburg
Country [147] 0 0
Sweden
State/province [147] 0 0
Linkoping
Country [148] 0 0
Sweden
State/province [148] 0 0
Stockholm
Country [149] 0 0
Switzerland
State/province [149] 0 0
Bern
Country [150] 0 0
Switzerland
State/province [150] 0 0
Lugano
Country [151] 0 0
Switzerland
State/province [151] 0 0
St.Gallen
Country [152] 0 0
Switzerland
State/province [152] 0 0
Zürich
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Cornwall
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Dorset
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Hampshire
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Norfolk
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Oxford
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Surrey
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Birmingham
Country [160] 0 0
United Kingdom
State/province [160] 0 0
Bradford
Country [161] 0 0
United Kingdom
State/province [161] 0 0
Bristol
Country [162] 0 0
United Kingdom
State/province [162] 0 0
Cambridge
Country [163] 0 0
United Kingdom
State/province [163] 0 0
Coventry
Country [164] 0 0
United Kingdom
State/province [164] 0 0
Glasgow
Country [165] 0 0
United Kingdom
State/province [165] 0 0
Hull
Country [166] 0 0
United Kingdom
State/province [166] 0 0
Liverpool
Country [167] 0 0
United Kingdom
State/province [167] 0 0
London
Country [168] 0 0
United Kingdom
State/province [168] 0 0
Manchester
Country [169] 0 0
United Kingdom
State/province [169] 0 0
Newcastle Upon Tyne
Country [170] 0 0
United Kingdom
State/province [170] 0 0
Nottingham
Country [171] 0 0
United Kingdom
State/province [171] 0 0
Plymouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Intercept Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.
Trial website
https://clinicaltrials.gov/study/NCT02548351
Trial related presentations / publications
Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 Mar;76(3):536-548. doi: 10.1016/j.jhep.2021.10.029. Epub 2021 Nov 15.
Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, Schattenberg JM, Barritt AS, Noureddin M, Bonacci M, Cawkwell G, Wong B, Rinella M; RandomizEd Global Phase 3 Study to Evaluate the Impact on NASH with FibRosis of Obeticholic Acid TreatmEnt (REGENERATE) Study Investigators. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2050-2058.e12. doi: 10.1016/j.cgh.2021.07.020. Epub 2021 Jul 15.
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. Erratum In: Lancet. 2020 Aug 1;396(10247):312. doi: 10.1016/S0140-6736(20)31645-7. Lancet. 2021 Jun 19;397(10292):2336. doi: 10.1016/S0140-6736(21)01216-2.
Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.
Public notes

Contacts
Principal investigator
Name 0 0
Sangeeta Sawhney, MD
Address 0 0
Intercept Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02548351